Q-omics provides the consensus-scored NTF4 profile across patient tissues and cancer cell-line models. NTF4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NTF4 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, NTF4 RNA expression shows 15,001 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LUAD, and TGCT as cancer lineages where NTF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTF4 survival associations across molecular data types. NTF4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTF4 RNA expression–survival associations across cancer types. High NTF4 expression shows unfavorable associations in COAD, KIRC, PAAD, LGG and SKCM, but favorable associations in THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NTF4 RNA expression.
This table summarizes NTF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NTF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTF4 shows lower tumor expression in LUAD, KIRC and BRCA and higher tumor expression in HNSC, COAD and LUSC. The LUAD box plot shows higher NTF4 RNA expression in normal versus tumor tissue (log2 FC = −0.613, t-test p < 0.001).
This table shows molecular features associated with NTF4 in patient tissues and cancer cell lines. In patient samples, NTF4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NTF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
